CVS Health (CVS) Receives a Buy from CFRA

CFRA analyst Kevin Huang maintained a Buy rating on CVS Health (CVSResearch Report) on November 30 and set a price target of $85.00. The company’s shares closed last Monday at $74.71.

According to TipRanks.com, Huang is a 2-star analyst with an average return of 8.0% and a 100.0% success rate. Huang covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Vertex Pharmaceuticals, and Biogen.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for CVS Health with a $82.85 average price target, which is an 11.4% upside from current levels. In a report issued on November 15, Bernstein also maintained a Buy rating on the stock with a $83.00 price target.

See today’s analyst top recommended stocks >>

CVS Health’s market cap is currently $98.29B and has a P/E ratio of 22.09. The company has a Price to Book ratio of 1.55.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CVS Health Corp. engages in the provision of health care services. It operates trough the following segments: Pharmacy Services, Retail or Long Term Care, Health Care Benefits and Corporate. The Pharmacy Services segment offers pharmacy benefit management solutions.